Published in final edited form as:

Rapid Commun Mass Spectrom. 2016 October 15; 30(19): 2109–2115. doi:10.1002/rcm.7692.

Influence of carboxylation on osteocalcin detection by mass spectrometry

Timothy P. Cleland¹, Corinne J. Thomas¹, Caren M. Gundberg², and Deepak Vashishth^{1,*}

¹Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY 12182, U.S.A

²Department of Orthopedics and Rehabilitation, Yale University, New Haven, CT 06520

Abstract

Rationale—Osteocalcin is a small, abundant bone protein that is difficult to detect using high-throughput MS/MS proteomic approaches from bone protein extracts, and is predominantly detected by non-MS immunological methods. Here, we analyze bovine osteocalcin and its post-translational modifications to determine why a protein of this size goes undetected.

Methods—Osteocalcin was purified from cow bone using well-established methods. Intact osteocalcin or trypsin digested osteocalcin were separated using an Agilent 1200 series HPLC and analyzed using a ThermoScientific LTQ-Orbitrap XL after fragmentation with higher-energy collision dissociation. Data were analyzed using Mascot or Prosight Lite.

Results—Our results support previous findings that the cow osteocalcin has up to three carboxylations using both intact osteocalcin and digested forms. Using Mascot, we were able to detect osteocalcin peptides, but no fragments that localized the carboxylations. Full annotation using Prosight Lite of the intact (three carboxylations), N-terminal peptide (one carboxylation), and middle peptide (two carboxylations) showed complete fragmentation was present, but complete neutral loss was observed.

Conclusions—Osteocalcin carboxylation, and its associated neutral losses, makes high-throughput detection of this protein challenging; however, alternative fragmentation or limited purification can overcome these challenges.

Keywords

bone; carboxyglutamic acid; osteocalcin; neutral loss

1 Introduction

Osteocalcin (OC) is an important protein in the extracellular matrix of bone that controls hydroxyapatite crystal properties^[1, 2] and plays a role in whole bone mechanics because of its interaction with both hydroxyapatite and bone collagen I.^[3] Because of its multiple roles in bone and non-skeletal role as a hormone promoting insulin production,^[4] osteocalcin has been a protein of major interest in extant human^[2, 5–9] and model organism

*Corresponding author: vashid@rpi.edu, Deepak Vashishth, Rensselaer Polytechnic Institute, 110 8th St, Troy, NY 12182, Fax: 518-276-4232.

studies^[1, 3, 10–13]. Additionally, because of its close association with hydroxyapatite, size, and acidity, it has been hypothesized to persist into the deep time making it a prime target for paleontological and archaeological investigations.^[14–25] It has also been a target for fossil remains because the N-terminal residues are variable providing greater phylogenetically informative sequences than other commonly preserved proteins in bone (e.g., collagen I).^[18] It is a small protein (~5800 Da) with three vitamin K dependent γ -carboxylated glutamic acid residues (Gla) at positions 17, 21, and 24^[26] that allow for direct binding to calcium in hydroxyapatite.^[27] In most species, all three residues are carboxylated; however, incomplete carboxylation has been observed in humans resulting from limited vitamin K uptake in human diet.^[28] Additionally, OC derived from humans and other closely related primates have been shown to lack hydroxyproline (Hyp), which has been observed on OC from other mammals including *Bos taurus*.^[16]

Traditionally, OC has been detected by radioimmunoassay^[7, 27, 29] that can identify the proteins from whole bone protein extracts without additional purification; however, these antibody-based methods provide little or no information on the post-translational modifications (PTMs) of the protein (i.e., Gla, Hyp). Complimentary methods have been developed to assess whether osteocalcin is undercarboxylated (e.g., hydroxyapatite binding assay^[27]), but these methods cannot indicate which Gla residues are modified or unmodified. These techniques remain the predominant way that osteocalcin is identified and levels of carboxylation are determined.^[30–34] In contrast to the antibody-based methods, mass spectrometry, especially using electrospray ionization, can provide direct measurement of the PTMs on OC; however, detection and/or characterization of this protein by mass spectrometry or by Edman-type sequencing (i.e., for intact sequence characterization) has relied on extensive purification steps (e.g., HPLC) before analysis.^[16, 28] This purification is also true for MALDI based mass spectrometry of OC, which has led to mass measurements but loss of Gla carboxylation precluding identification of osteocalcin carboxy-proteoforms.^[35, 36]

Using purified *B. taurus* OC, we analyze this protein and its post-translational modifications, after electrospray ionization, to investigate why it is difficult to detect by high-throughput mass spectrometry of bone protein extractions. We additionally use a mixture of bovine collagen I and osteocalcin to show the effects of collagen I on osteocalcin ionization.

Materials and Methods

Bos taurus Osteocalcin and digestion

OC from *B. taurus* bone was purified following Gundberg et al.^[37] In short, cleaned, marrow free bovine bone was ground and then pulverized to <100 μ m in size with a magnetically driven mill (Spex Industries, Methuen, NJ). The resultant bone powder was rinsed with methanol and then ether, dried, and extracted twice with 20 vol 0.5M EDTA, pH 6.2, containing protease inhibitors. The EDTA extract was exhaustively dialyzed, lyophilized, redissolved in 50mM NH_4HCO_3 , and then fractionated on Sephadex G-75. A large peak, which eluted near the expected size of osteocalcin (~6 kDa), was subjected to DEAE ion exchange. The DEAE-purified material was further purified by HPLC using a preparative C_{18} column with a 0–70% acetonitrile gradient in 0.1% trifluoroacetic acid.

Rechromatography of the central portion of a large trailing peak yielded a single symmetrical peak which was intact osteocalcin. For intact analyses, OC was reduced with 10 mM dithiothreitol for 20 min at 55°C followed by acidification with an equal volume of 1% formic acid. Prior to digestion, OC was reduced with 10 mM dithiothreitol for 1 hour at room temperature, alkylated with 30 mM iodoacetamide for 1 hour in the dark, and digested overnight at 37°C with Promega (Madison, WI) Trypsin Gold at a ratio of 1:100 (trypsin:protein). All intact and digested OC were concentrated using Empore (3M, Saint Paul, MN) C18 stage tips.^[38] Peptides were eluted from the tip using 20 µL of 80% acetonitrile, 0.1% formic acid. After evaporation of the acetonitrile, peptides were resuspended in 0.1% formic acid.

To evaluate the effect of collagen I peptides on osteocalcin detection by mass spectrometry, we also digested a sample with 100:1 bovine collagen I (BD Biosciences):OC as described above. We chose 100:1 to reflect a similar ratio of collagen to osteocalcin in bone, and clearly show the effect of collagen I on osteocalcin detection.

Mass Spectrometry

OC peptides, collagen I/OC mixture, and intact OC were separated using an Agilent (Santa Clara, CA) 1200 Series HPLC with a Thermo Scientific BioBasic C18 (2.1 mm ID, 150 mm column length, 5 µm particle size) for 75 minutes using the following gradient: 2% B 0–5 min, 30% B 5–35 min, 60% B 35–60 min, 95% B 60.01–64 min, 2% B 64.01–75 min where A is 0.2% formic acid and B is 100% acetonitrile, 0.2% formic acid. Eluted peptides were characterized in positive mode on a LTQ-Orbitrap XL (Thermo Scientific) with the following parameters: top three peaks fragmented with HCD (35 NCE) with a 3 *m/z* isolation window; 30,000 resolution for precursor and fragment scans; precursor scan range 300–2000 *m/z*. The three most abundant peaks were fragmented using HCD in the Orbitrap.

Data analysis

To identify OC peaks, raw files were converted to peak lists (mgf) using MassMatrix Mass Spectrometric File Conversion Tools v. 3.2 and searched against Swissprot and a decoy database using Mascot 2.3 (Matrix Science, Boston, MA). The following parameters were set for each search: taxonomy was set to Mammals; enzyme = trypsin; up to 3 missed cleavages; variable modifications: carbamidomethyl (CAM) N-terminus, CAM lysine, deamidation of asparagine and glutamine, carboxy glutamic acid, oxidation of methionine and proline; static modifications: CAM cysteine; peptide tolerance = 10 ppm; fragment tolerance = 0.5 Da; and peptide charge = 2+, 3+, 4+. Peptide results were filtered using a Mascot score cutoff of 45.

Additional, *in silico* digestion of *B. taurus* OC was performed with either ProteinMass^[39] or Protein Prospector v. 5.14.3 (<http://prospector.ucsf.edu/>). Averaged MS/MS spectra corresponding to these peaks were extracted with a 1.5 S/N in Qualbrowser (ThermoScientific) and annotated using ProSight Lite^[40] with error tolerance set to 10 ppm and fragmentation type HCD. Proline 9 was modified to hydroxyproline (+15.994915 Da), and Glu 17, 21, 24 were modified to Gla (+43.989829) manually or left unmodified. For the

digested peptides, cysteine or the protein N-terminus was modified by carbamidomethylation (+57.021464).

Carboxylation level was quantified using areas from extracted ion chromatograms in Qualbrowser. The following masses were used for area calculations based on the intact protein mass extracted across the mass envelope: 0 carboxylations (1143.93–1145.58 [5+]), 1 carboxylation (1153.00–1154.92 [5+]), 2 carboxylations (1161.62–1163.53 [5+]), and 3 carboxylations (1170.28–1172.46 [5+]), and for the chromium adducted intact form^[35, 41]: 0 carboxylations (1155.05–1156.29 [5+]), 1 carboxylation (1163.97–1164.84 [5+]), 2 carboxylations (1172.57–1174.02 [5+]), and 3 carboxylations (1180.83–1183.48 [5+]). For the N-terminal peptide we used the following masses: 0 carboxylations (1097.96–1099.13 [2+]), 1 carboxylation (1119.95–1122.60 [2+]), 0 carboxylations + 1 CAM (1126.48–11283.61 [2+]), 1 carboxylation + 1 CAM (1148.46–1151.11 [2+]), 1 carboxylation + 2 CAM (1176.97–1179.11 [2+]), 1 carboxylation + 3 CAM (1205.48–1208.13 [2+]), and for the middle peptide: 0 carboxylations + 2 CAM (979.37–981.14 [3+]), 1 carboxylation + 2 CAM (994.03–995.82 [3+]), 1 carboxylation + 3 CAM (1013.01–1014.85 [3+]), 2 carboxylations + 2 CAM (1008.70–1010.51 [3+]), and 2 carboxylations + 3 CAM (1027.66–1029.56 [3+]).

Results and Discussion

Osteocalcin is the second most abundant bone protein,^[42] and through its carboxyglutamic acids binds tightly to bone hydroxyapatite.^[27] In humans, this protein is found in various states of undercarboxylation as a result of limited vitamin K in human diets.^[27] This important variation in carboxylation state may impact the mechanical properties of bone, and the levels have been extensively measured using plate based assays; however, these methods provide incomplete characterization of the various osteocalcin proteoforms that exist in bone.^[27] Here, we chose to analyze bovine OC because it is a typically fully carboxylated exemplar of what to expect for carboxylated OC, without the complexity of undercarboxylation from human bone. For intact OC, we were able to detect proteoforms possessing between 0–3 carboxylations. Additionally, we identified chromium adducted (+51.9) forms with the 0–3 carboxylations.^[41] This adduction has been hypothesized to derive from the ESI emitter capillary; however, based on our chromatography and later elution, it appears this adduction is likely from earlier in the HPLC (Fig. S1). In total (i.e., combined chromium adducted and non-adducted OC), we found fully carboxylated *B. taurus* OC ($81.5 \pm 0.2\%$) with hydroxyproline (Fig. 1A; Fig. S2) as has been previously reported from *B. taurus* bone;^[26] however, the doubly- ($15.7 \pm 0.5\%$), singly- ($1.9 \pm 0.3\%$), and uncarboxylated ($0.9 \pm 0.1\%$) proteoforms were also detected (Fig. 1A). The chromium adducted forms show a more consistent level of carboxylation (Table S1; for 3 carboxy: $84.0 \pm 0.9\%$) compared to the non-adducted form (Table S1; for 3 carboxy: $77.0 \pm 12.4\%$), suggesting that the chromium is stabilizing the osteocalcin carboxylation, and that some of the carboxylation variation that we detect is the result of decarboxylation during or before LC. This loss of carboxylation must be considered in future mass spectrometry carboxylation quantitation experiments for OC from all species, especially humans where undercarboxylation is common.^[28] Additionally, fragmentation of the triply carboxylated bovine OC shows the distinct neutral losses of carboxylated glutamic acids (Fig. 1B).

The incomplete carboxylation is also observed after digestion of the *B. taurus* OC with trypsin on both the N-terminal peptide ($94.9 \pm 0.1\%$ single carboxylated; Fig. 2A) and middle peptide ($65.8 \pm 1.6\%$ single carboxylated, $34.2 \pm 0.8\%$ double carboxylated; Fig. 3A); however, no evidence of chromium adduction is present on the tryptic peptides. Consistent with the intact proteoform, neutral losses were observed for all positions of carboxylation for the N-terminal and middle peptides. Mascot (Supplemental Tables S2–S4) was able to consistently detect the N-terminal peptide and variably detect the middle tryptic peptide of the bovine OC (Fig. 2B, 3B); however, fragments localizing the carboxylations were not detected, instead only b-ion fragments of the N-terminal peptide or y-ion fragments of the middle peptide were detected. The fragmentation pattern differences between Prosight Lite and Mascot reflect the presence of fragments corresponding to the neutral loss peaks associated with the loss of carboxylation after fragmentation (Fig. 2B, 3B). The digestion of this *B. taurus* OC shows that, even for peptides with good HCD fragmentation, carboxylation can limit identification of fragments that localize carboxylation positions. We also observed extensive overalkylation of the cysteine-free N-terminal peptide ($86.1 \pm 0.1\%$) and the di-cysteine middle OC peptide ($61.1 \pm 1.4\%$) regardless of carboxylation state, making the addition of the variable N-terminal CAM modification in Mascot critical for detection of these peptides. Routine inclusion of N-terminal CAM may not be feasible with the increase in database search space; however, rapid identification of overalkylation for accurate searching is available in various software packages, including Protein Metrics Preview^[43]. Missing identifications through database searching, as a result of neutral loss and overalkylation, becomes a major problem for global bone proteome studies where this important protein may not be identified.

It is noteworthy that detection of osteocalcin peptides by mass spectrometry is hindered by two major factors: 1) γ -carboxylation of one or more glutamic acids, and 2) the acidity of OC. Gamma carboxylation of glutamic acid results in neutral loss after fragmentation using CID or HCD (Fig. 1–3). Consequently, these neutral losses make identification of the modified peptides more difficult.^[44, 45] CO_2 loss during fragmentation gives b- or y- ion series consistent with the unmodified protein (Fig. 1B) or peptide (Fig. 2B, 3B) depending on the position of the carboxylations instead of the modified forms, resulting in missed identifications or limited fragment matches using Mascot. Other fragmentation methodology (e.g., electron transfer dissociation,^[44] electron capture dissociation,^[41, 45] ultraviolet photodissociation^[46]), methylation of the glutamic acid carboxyl groups,^[44] or mass spectrometry immunoassay (MSIA^[35]) or other osteocalcin purification methods (e.g., preparative HPLC,^[37] gel filtration^[47]) may be necessary to better identify the carboxylated OC. However, the inclusion of additional modifications through methylation may further complicate the analysis by inducing unknown numbers of methylations or further splitting the peptide/protein signal into a greater number of forms. MSIA or HPLC purification provide an opportunity to isolate OC from bone extracts in quantitative amounts lending itself to a complete characterization of the bone OC proteoforms present.

Furthermore, the acidity of OC may impact its detectability, especially in bone extractions. In positive ionization mode, acidic peptides show reduced ion signals^[46] compared to comparatively basic ones (e.g., those from collagen I). While we do not have problems electrospraying the *B. taurus* OC by itself, in the presence of bovine collagen I, we were

unable to detect the bovine OC. Mascot searching only resulted in detection of collagen I alpha 1 and alpha 2 peptides. This result is similar to our previous results detecting only the N-terminal peptide of OC from human samples without prior purification in the presence of a large number of collagen I peptides.^[48] Removal/depletion of the collagen I or enrichment of osteocalcin by purification^[37] may help to better identify this protein from bone samples by mass spectrometry.

Conclusions

With mass spectrometry and HCD fragmentation, we are able to detect variably carboxylated *B. taurus* OC, yet technical challenges remain to detect modified OC in an automated or high-throughput way. Alternative fragmentation methodology and/or additional search strategies may overcome the challenges of characterizing carboxylated OC by mass spectrometry.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would like to thank D. Morgenstern and R. Cole for excellent discussions about challenges in identification of carboxylation in MS/MS spectra, and D. Zagorevsky for proteomic core access. Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01 AR49635 and the National Science Foundation under CCM1 1363526. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Additional funding was provided by an internal grant from RPI.

Abbreviations

OC	Osteocalcin
Gla	Carboxyglutamic acid
Hyp	Hydroxyproline

References

1. Ducy P, Desbois C, Boyce B, Pinero G, Story B, Dunstan C, Smith E, Bonadio J, Goldstein S, Gundberg C, Bradley A, Karsenty G. *Nature*. 1996; 382:448. [PubMed: 8684484]
2. Boskey AL, Gadaleta S, Gundberg C, Doty SB, Ducy P, Karsenty G. *Bone*. 1998; 23:187. [PubMed: 9737340]
3. Poundarik AA, Diab T, Sroga GE, Ural A, Boskey AL, Gundberg CM, Vashishth D. *Proceedings of the National Academy of Sciences*. 2012; 109:19178.
4. Karsenty G, Ferron M. *Nature*. 2012; 481:314. [PubMed: 22258610]
5. Sroga GE, Vashishth D. *Current osteoporosis reports*. 2012; 10:141. [PubMed: 22535528]
6. Gundberg CM, Anderson M, Dickson I, Gallop PM. *The Journal of Biological Chemistry*. 1986; 261:14557. [PubMed: 3490475]
7. Bouillon R, Vanderschueren D, Van Herck E, Nielsen HK, Bex M, Heyns W, Van Baelen H. *Clinical Chemistry*. 1992; 38:2055. [PubMed: 1394989]
8. Tanaka S, Narusawa K, Onishi H, Miura M, Hijioka A, Kanazawa Y, Nishida S, Ikeda S, Nakamura T. *Osteoporosis International*. 2011; 22:587. [PubMed: 20625700]

9. Emaus N, Nguyen ND, Almaas B, Berntsen GK, Center JR, Christensen M, Gjesdal CG, Grimsgaard AS, Nguyen TV, Salomonsen L, Eisman JA, Fønnebø VM. *European Journal of Nutrition*. 2013; 52:49. [PubMed: 22127508]
10. Prigodich RV, Vesely MR. *Archives of Biochemistry and Biophysics*. 1997; 345:339. [PubMed: 9308908]
11. Hoang QQ, Sicheri F, Howard AJ, Yang DSC. *Nature*. 2003; 425:977. [PubMed: 14586470]
12. Ferron M, McKee MD, Levine RL, Ducy P, Karsenty G. *Bone*. 2012; 50:568. [PubMed: 21550430]
13. Nikel O, Laurencin D, McCallum SA, Gundberg CM, Vashishth D. *Langmuir*. 2013; 29:13873. [PubMed: 24128197]
14. Collins MJ, Gernaey AM, Nielsen-Marsh CM, Vermeer C, Westbroek P. *Geology*. 2000; 28:1139.
15. Nielsen-Marsh CM, Ostrom PH, Gandhi H, Shapiro B, Cooper A, Hauschka PV, Collins MJ. *Geology*. 2002; 30:1099.
16. Nielsen-Marsh CM, Richards MP, Hauschka PV, Thomas-Oates JE, Trinkaus E, Pettitt PB, Karavani I, Poinar H, Collins MJ. *Proceedings of the National Academy of Sciences of the United States of America*. 2005; 102:4409. [PubMed: 15753298]
17. Smith CI, Craig OE, Prigodich RV, Nielsen-Marsh CM, Jans MME, Vermeer C, Collins MJ. *Journal of Archaeological Science*. 2005; 32:105.
18. Ostrom PH, Gandhi H, Strahler JR, Walker AK, Andrews PC, Leykam J, Stafford TW, Kelly RL, Walker DN, Buckley M, Humpala J. *Geochimica et Cosmochimica Acta*. 2006; 70:2034.
19. Humpala JF, Ostrom PH, Gandhi H, Strahler JR, Walker AK, Stafford TW, Smith JJ, Voorhies MR, Corner RG, Andrews PC. *Geochimica et Cosmochimica Acta*. 2007; 71:5956.
20. Buckley M, Anderung C, Penkman K, Raney BJ, Götherström A, Thomas-Oates J, Collins MJ. *Journal of Archaeological Science*. 2008; 35:1756.
21. Ostrom PH, Schall M, Gandhi H, Shen T-L, Hauschka PV, Strahler JR, Gage DA. *Geochimica et Cosmochimica Acta*. 2000; 64:1043.
22. Schweitzer MH, Zheng W, Organ CL, Avci R, Suo Z, Freimark LM, Lebleu VS, Duncan MB, Vander Heiden MG, Neveu JM, Lane WS, Cottrell JS, Horner JR, Cantley LC, Kalluri R, Asara JM. *Science*. 2009; 324:626. [PubMed: 19407199]
23. Schweitzer MH, Suo Z, Avci R, Asara JM, Allen MA, Arce FT, Horner JR. *Science*. 2007; 316:277. [PubMed: 17431179]
24. Huq NL, Rambaud SM, Teh L-C, Davies AD, McCulloch B, Trotter MM, Chapman GE. *Biochemical and Biophysical Research Communications*. 1985; 129:714. [PubMed: 3874623]
25. Cleland TP, Voegelé K, Schweitzer MH. *PLoS One*. 2012; 7:e31443. [PubMed: 22348088]
26. Price PA, Poser JW, Raman N. *Proc Natl Acad Sci U S A*. 1976; 73:3374. [PubMed: 1068450]
27. Gundberg CM, Lian JB, Booth SL. *Advances in Nutrition: An International Review Journal*. 2012; 3:149.
28. Cairns JR, Price PA. *Journal of Bone and Mineral Research*. 1994; 9:1989. [PubMed: 7872066]
29. Gundberg CM, Clough ME, Carpenter TO. *Endocrinology*. 1992; 130:1909. [PubMed: 1547718]
30. Sroga GE, Karim L, Colón W, Vashishth D. *Molecular & Cellular Proteomics*. 2011; 10 M110.006718.
31. Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G. *Biochemical and Biophysical Research Communications*. 2010; 397:691. [PubMed: 20570657]
32. Prats-Puig A, Mas-Parareda M, Riera-Pérez E, González-Forcadell D, Mier C, Mallol-Guisset M, Díaz M, Bassols J, de Zegher F, Ibáñez L, López-Bermejo A. *Diabetes Care*. 2010; 33:661. [PubMed: 20009098]
33. Levinger I, Scott D, Nicholson GC, Stuart AL, Duque G, McCorquodale T, Herrmann M, Ebeling PR, Sanders KM. *Bone*. 2014; 64:8. [PubMed: 24662619]
34. Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M, Takada J, Chaki O, Hagino H, Fujiwara S, Fukunaga M, Miki T, Yoshimura N. *Journal of Bone and Mineral Metabolism*. 2012; 31:1. [PubMed: 23143508]
35. Rehder DS, Gundberg CM, Booth SL, Borges CR. *Molecular & Cellular Proteomics*. 2015; 14:1546. [PubMed: 25855755]

36. Ivaska KK, Hentunen TA, Vaaraniemi J, Ylipahkala H, Pettersson K, Vaananen K. *Journal of Biological Chemistry*. 2004; 279:18361. [PubMed: 14970229]
37. Gundberg, CM.; Hauschka, PV.; Lian, JB.; Gallop, PM. *Methods in Enzymology*, Vol. Volume 107. Finn, W.; Kivie, M., editors. Academic Press; 1984. p. 516
38. Rappsilber J, Mann M, Ishihama Y. *Nat. Protocols*. 2007; 2:1896. [PubMed: 17703201]
39. Wilkins MR, Lindskog I, Gasteiger E, Bairoch A, Sanchez JC, Hochstrasser DF, Appel RD. *Electrophoresis*. 1997; 18:403. [PubMed: 9150918]
40. Fellers RT, Greer JB, Early BP, Yu X, LeDuc RD, Kelleher NL, Thomas PM. *Proteomics*. 2015; 15:1235. [PubMed: 25828799]
41. Niiranen H, Budnik BA, Zubarev RA, Auriola S, Lapinjoki S. *Journal of Chromatography A*. 2002; 962:95. [PubMed: 12198976]
42. Hauschka PV, Wians FH. *The Anatomical Record*. 1989; 224:180. [PubMed: 2549810]
43. Kil YJ, Becker C, Sandoval W, Goldberg D, Bern M. *Analytical Chemistry*. 2011; 83:5259. [PubMed: 21619057]
44. Hallgren KW, Zhang D, Kinter M, Willard B, Berkner KL. *Journal of Proteome Research*. 2012; 12:2365. [PubMed: 22536908]
45. Kelleher NL, Zubarev RA, Bush K, Furie B, Furie BC, McLafferty FW, Walsh CT. *Analytical Chemistry*. 1999; 71:4250. [PubMed: 10517147]
46. Shaw JB, Madsen JA, Xu H, Brodbelt JS. *J Am Soc Mass Spectrom*. 2012; 23:1707. [PubMed: 22895858]
47. Colombo G, Fanti P, Yao C, Malluche HH. *Journal of Bone and Mineral Research*. 1993; 8:733. [PubMed: 8101026]
48. Cleland TP, Vashishth D. *Analytical Biochemistry*. 2015; 472:62. [PubMed: 25535955]

Figure 1.

A) Intact *Bos taurus* OC showing between 0 and 3 carboxylations. Most are triply-carboxylated. B) Fragmentation of m/z 1171.3408 showing as much as three CO_2 losses. Light gray box = hydroxylation; dark gray box = carboxylation.

Figure 2.

A) Spectrum of the N-terminal tryptic peptide showing single carboxylation with carbamidomethyl N-terminus (1-Carboxy+CAM) and uncarboxylated (0-Carboxy+CAM) forms. B) Fragmentation pattern of m/z 1149.05 in (A). No carboxylated y-ion peaks are present; all detected peaks show CO_2 loss except y2, which does not overlap the carboxylation. Light gray box = hydroxylation; dark gray box = carboxylation; empty gray box = carbamidomethylation of the N-terminus. Gray fragment markers indicate fragments detected by Mascot.

Figure 3.

A) The middle peptide (REVCELNPDCDELADHIGFQEAYR) showing 0–2 carboxylations. B) Fragmentation of m/z 1009.09 in (A) showing two CO_2 losses for all b-series ions. No y-series ions overlapping the carboxylation were detected. Dark gray box = carboxylation; gray C = carbamidomethylation of cysteine. Gray fragment markers indicate fragments detected by Mascot.